Overview

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of AKI in subjects who are at high risk for AKI following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Quark Pharmaceuticals